LENSAR Inc (LNSR)
3.32
+0.06
(+1.84%)
USD |
NASDAQ |
May 06, 16:00
3.32
0.00 (0.00%)
After-Hours: 20:00
LENSAR Research and Development Expense (Quarterly): 1.463M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.463M |
| September 30, 2023 | 1.527M |
| June 30, 2023 | 1.499M |
| March 31, 2023 | 1.65M |
| December 31, 2022 | 1.615M |
| September 30, 2022 | 1.577M |
| June 30, 2022 | 3.834M |
| March 31, 2022 | 4.788M |
| December 31, 2021 | 3.422M |
| Date | Value |
|---|---|
| September 30, 2021 | 3.184M |
| June 30, 2021 | 3.006M |
| March 31, 2021 | 2.746M |
| December 31, 2020 | 2.543M |
| September 30, 2020 | 2.005M |
| June 30, 2020 | 1.434M |
| March 31, 2020 | 1.571M |
| December 31, 2019 | 1.41M |
| September 30, 2019 | 4.331M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.41M
Minimum
Dec 2019
4.788M
Maximum
Mar 2022
2.422M
Average
1.828M
Median
Research and Development Expense (Quarterly) Benchmarks
| Ainos Inc | 2.237M |
| OpGen Inc | 1.202M |
| Zomedica Corp | 3.099M |
| Eargo Inc (DELISTED) | 4.742M |
| Intelligent Bio Solutions Inc | 0.3485M |